Publications by authors named "S Cassibba"
Does denosumab exert a protective effect against COVID-19? Results of a large cohort study.
Front Endocrinol (Lausanne)
December 2023
Introduction: Denosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis. Since RANK and RANKL are also involved in the immune system activation, denosumab might interfere with the response against infections. Our study aimed to explore the relationship between denosumab treatment and coronavirus disease 2019 (COVID-19).
View Article and Find Full Text PDFArticle Synopsis
- The study investigated thyroid dysfunction and autoimmune thyroid disease (ATD) in 599 COVID-19 survivors three months after hospital admission, focusing on the prevalence of specific antibodies.
- Results showed that female sex was positively associated with thyroid autoimmunity, while type 2 diabetes had a negative association; other demographic factors and COVID-19 severity did not impact autoimmunity risk.
- The prevalence of thyroperoxidase antibodies (TPOAb) in COVID-19 survivors was significantly higher at 15.7% compared to 7.7% in non-thyroid disease controls, and ultrasound revealed thyroiditis in nearly all patients with positive antibodies.
Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen.
J Diabetes Metab Disord
December 2018
[This corrects the article DOI: 10.1007/s40200-018-0358-2.].
View Article and Find Full Text PDFThe basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen.
J Diabetes Metab Disord
December 2018
Objective: To evaluate the basal/total ratio of daily insulin dose (b/T) in outpatients with diabetes type 1 (DM1) and type 2 (DM2) on basal-bolus regimen, by investigating whether there is a relationship with HbA1c and episodes of hypoglycemia.
Methods: Multicentric, observational, cross-sectional study in Italy. Adult DM1 ( = 476) and DM2 ( = 541) outpatients, with eGFR >30 mL/min/1.
Objective: To characterize primary hyperparathyroidism (PHPT) patients with renal stones and to compare silent with symptomatic stone formers.
Methods: We reviewed clinical data from 234 patients with PHPT, comparing those with and without renal stones (n = 109 and 125, respectively), and among stone formers those symptomatic versus silent (n = 93 and 16, respectively).
Results: Stone formers were younger, had higher urinary calcium levels and higher estimated glomerular filtration rates (eGFRs) compared to patients without stones.